Bavarian Nordic company profile
Company profile
Bavarian Nordic has 1,692 employees and is headquartered in Hellerup, Denmark.
With 1,692 employees, the company develops, makes and sells vaccines against smallpox, monkeypox, rabies, tick-borne encephalitis, cholera and typhoid fever, including the JYNNEOS, IMVANEX, Rabipur and Vaxchora products. It is also running a phase 2 trial of MVA-BN WEV for encephalitis viruses. Its markets include the United States, Canada, Germany, Japan, Australia and Saudi Arabia, along with several European countries and other regions in its international business.
The group reported revenue of DKK 6.2 billion in the fiscal year ended December 2025, a rise of 9.2% from the year before, and net profit of DKK 1.4 billion for the same period. Founded in 1992, it has its seat in Hellerup, Denmark.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Headquarters
- Philip Heymans Alle 3, 2900, Hellerup
- Employees
- 1,692
- Chief executive
- Paul Chaplin
- Founded
- 1992
- Fiscal year
- January - December
- Listing
- BAVA · Nasdaq Copenhagen
- Currency
- DKK
- ISIN
- DK0015998017
- Website
- bavarian-nordic.com
Bavarian Nordic and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Bavarian NordicBAVA | Denmark | $2.64B | 1,692 | 6.9% | 12.4 |
| BioArcticBIOA.B | Sweden | $2.72B | 150 | 19.6% | 262.7 |
| Zealand PharmaZEAL | Denmark | $2.36B | 605 | 59.0% | 5.49 |
| Lakefront BiotherapeuticsLKFT | Netherlands | $2.28B | 196 | 57.5% | 2.62 |
| CamurusCAMX | Sweden | $4.36B | 323 | 37.4% | 58.5 |
| IdorsiaIDIA | Switzerland | $1.25B | 424 | -68.4% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
